Samyag

Corporate Actions

Back

Alembic Pharma gains after receiving USFDA nod for Darolutamide tablets

14-May-26 10:28 Hrs IST

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Nubeqa Tablets, 300 mg, marketed by Bayer HealthCare Pharmaceuticals.

Darolutamide is an androgen receptor inhibitor indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and mCSPC in combination with docetaxel.

According to IQVIA, Darolutamide Tablets, 300 mg, have an estimated market size of US$ 3,155 million for the 12 months ended March 2026.

With this approval, Alembic Pharmaceuticals now has a cumulative total of 238 ANDA approvals from the USFDA, comprising 219 final approvals and 19 tentative approvals.

Alembic Pharmaceuticals is a vertically integrated research and development company engaged in the manufacture and marketing of generic pharmaceutical products across global markets. The company had reported a 3.9% decline in consolidated net profit to Rs 132.97 crore despite a 10.8% increase in net sales to Rs 1,876.31 crore in Q3 FY26 compared with Q3 FY25.

Powered by Capital Market - Live News

Attention Investors:

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. || KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. || No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.